Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C18H21NO3.3H2O.2H3O4P |
| Molecular Weight | 848.7647 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.OP(O)(O)=O.OP(O)(O)=O.COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C.COC6=CC=C7C[C@@H]8[C@@H]9C=C[C@H](O)[C@@H]%10OC6=C7[C@]9%10CCN8C
InChI
InChIKey=UDIMULCGRYVAIM-REWFBLHLSA-N
InChI=1S/2C18H21NO3.2H3O4P.3H2O/c2*1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;2*1-5(2,3)4;;;/h2*3-6,11-13,17,20H,7-9H2,1-2H3;2*(H3,1,2,3,4);3*1H2/t2*11-,12+,13-,17-,18-;;;;;/m00...../s1
| Molecular Formula | H3O4P |
| Molecular Weight | 97.9952 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C18H21NO3 |
| Molecular Weight | 299.3642 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Codeine is an opiate used to manage mild to moderate pain severe enough to require an opioid. Codeine is a selective agonist for the mu opioid receptor and has an affinity to delta and kappa-opioid receptors. In some countries, this drug is regulated under various narcotic control laws, because its chronic use can cause physical dependence. In others, it is available without a medical prescription in combination with paracetamol.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL233 |
6.1 µM [EC50] | ||
Target ID: P41145 Gene ID: 4986.0 Gene Symbol: OPRK1 Target Organism: Homo sapiens (Human) |
|||
Target ID: P41143 Gene ID: 4985.0 Gene Symbol: OPRD1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CAPITAL AND CODEINE Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
66.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
145 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
229 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
93 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
242 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
53.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
MORPHINE-3-GLUCURONIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
66.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
968 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE-6-GLUCURONIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.61 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
466 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
849 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
467 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
937 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.47 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/ |
60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.71 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
MORPHINE-3-GLUCURONIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.47 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE-6-GLUCURONIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
75% |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
CODEINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive [IC50 35.7774 uM] | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| unlikely [IC50 400 uM] | ||||
| yes [IC50 10.5 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| major | ||||
| major | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Over-the-counter medications for acute cough in children and adults in ambulatory settings. | 2001 |
|
| Dystonia as acute adverse reaction to cough suppressant in a 3-year-old girl. | 2001 |
|
| Pharmacological control of cough. | 2001 Apr |
|
| The use of compound 48/80 and codeine phosphate as positive controls for intradermal skin testing in dogs. | 2001 Apr |
|
| Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001 Apr |
|
| Angle closure risk from proprietary medicines. | 2001 Apr |
|
| Prescribing limitations. | 2001 Aug 11 |
|
| Precipitated withdrawal following codeine administration is dependent on CYP genotype. | 2001 Aug 17 |
|
| Effect of prophylactic amoxicillin on endodontic flare-up in asymptomatic, necrotic teeth. | 2001 Jan |
|
| Opiate-sensitivity: clinical characteristics and the role of skin prick testing. | 2001 Jul |
|
| Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. | 2001 Jul |
|
| Use of beta-cyclodextrin in the capillary zone electrophoretic separation of the components of clandestine heroin preparations. | 2001 Jul 27 |
|
| Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. | 2001 Jul 7 |
|
| Heroin use by motorists in Sweden confirmed by analysis of 6-acetylmorphine in urine. | 2001 Jul-Aug |
|
| Laboratory analysis of remotely collected oral fluid specimens for opiates by immunoassay. | 2001 Jul-Aug |
|
| [Chronic pain in geriatrics]. | 2001 Jun |
|
| Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. | 2001 Jun |
|
| Oral ibuprofen versus paracetamol plus codeine for analgesia after ambulatory surgery. | 2001 Jun |
|
| Ulcerated hemangiomas: clinical characteristics and response to therapy. | 2001 Jun |
|
| Analysis of cocaine, benzoylecgonine, codeine, and morphine in hair by supercritical fluid extraction with carbon dioxide modified with methanol. | 2001 Jun 1 |
|
| Time of drug elimination in chronic drug abusers. Case study of 52 patients in a "low-step" detoxification ward. | 2001 Jun 15 |
|
| [Information on preparations containing codeine]. | 2001 Jun 20 |
|
| Codeine phosphate in children: time for re-evaluation? | 2001 Mar |
|
| Expression and activity of cell-wall-degrading enzymes in the latex of opium poppy, Papaver somniferum L. | 2001 Mar |
|
| Dihydrocodeine--drug of use or misuse? | 2001 May |
|
| From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. | 2001 May-Jun |
|
| Regional block and mexiletine: the effect on pain after cancer breast surgery. | 2001 May-Jun |
|
| Scalp nerve blocks decrease the severity of pain after craniotomy. | 2001 Nov |
|
| Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine. | 2001 Nov |
|
| The role of adrenal corticosteroids in induction of micronuclei by morphine. | 2001 Nov 15 |
|
| Nutritional effects of surgical and medical treatment for short bowel syndrome. | 2001 Nov-Dec |
|
| Novel dynamic polymer coating for capillary electrophoresis in nonaqueous methanolic background electrolytes. | 2001 Oct |
|
| Seizures with intravenous codeine phosphate. | 2001 Oct |
|
| Incorporation of selegiline metabolites into hair after oral selegiline intake. | 2001 Oct |
|
| Ropivacaine with or without clonidine improves pediatric tonsillectomy pain. | 2001 Oct |
|
| Drug contamination of US paper currency. | 2001 Oct 1 |
|
| Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients. | 2001 Oct 1 |
|
| Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. | 2001 Sep |
|
| Community pharmacists' experience of over-the-counter medicine misuse in Scotland. | 2001 Sep |
|
| Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. | 2001 Sep |
|
| Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. | 2001 Sep |
|
| Blind trials of an onsite saliva drug test for marijuana and opiates. | 2001 Sep |
|
| [Weak opioids]. | 2001 Sep |
|
| [Strong opioids]. | 2001 Sep |
|
| Concentration ratios of codeine-to-morphine in plasma after a single oral dose (100 mg) of codeine phosphate. | 2001 Sep |
|
| Detection of non-prescription heroin markers in urine with liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. | 2001 Sep |
|
| Pain control in medical abortion. | 2001 Sep |
|
| Engineering novel biocatalytic routes for production of semisynthetic opiate drugs. | 2001 Sep |
|
| Can standard open pediatric urological procedures be performed on an outpatient basis? | 2001 Sep |
|
| Experience with urine drug testing by the Correctional Service of Canada. | 2001 Sep 15 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:08:32 GMT 2025
by
admin
on
Mon Mar 31 19:08:32 GMT 2025
|
| Record UNII |
BKA0632GWS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5913-76-8
Created by
admin on Mon Mar 31 19:08:32 GMT 2025 , Edited by admin on Mon Mar 31 19:08:32 GMT 2025
|
PRIMARY | |||
|
BKA0632GWS
Created by
admin on Mon Mar 31 19:08:32 GMT 2025 , Edited by admin on Mon Mar 31 19:08:32 GMT 2025
|
PRIMARY | |||
|
DTXSID20207872
Created by
admin on Mon Mar 31 19:08:32 GMT 2025 , Edited by admin on Mon Mar 31 19:08:32 GMT 2025
|
PRIMARY | |||
|
100000092021
Created by
admin on Mon Mar 31 19:08:32 GMT 2025 , Edited by admin on Mon Mar 31 19:08:32 GMT 2025
|
PRIMARY | |||
|
5492885
Created by
admin on Mon Mar 31 19:08:32 GMT 2025 , Edited by admin on Mon Mar 31 19:08:32 GMT 2025
|
PRIMARY | |||
|
SUB01408MIG
Created by
admin on Mon Mar 31 19:08:32 GMT 2025 , Edited by admin on Mon Mar 31 19:08:32 GMT 2025
|
PRIMARY | |||
|
CODEINE PHOSPHATE SESQUIHYDRATE
Created by
admin on Mon Mar 31 19:08:32 GMT 2025 , Edited by admin on Mon Mar 31 19:08:32 GMT 2025
|
PRIMARY | Description: Small, colourless crystals or a white, crystalline powder; odourless.Solubility: Soluble in 4 parts of water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Antitussive; analgesic.Storage: Codeine phosphate should be kept in a tightly closed container, protected from light.Labelling: The designation on the container should state if the Codeine phosphate is the hemihydrate or the sesquihydrate.Additional information: Codeine phosphate effloresces in dry air. |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
Pending
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
correction factor: for the calculation of content, multiply the peak area of impurity C by 0.25
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |